The FDA Just Approved the Flu Shot It Tried to Block
The first mRNA flu vaccine just cleared an FDA that blocked it in the spring. The approval validates the platform — but the committee that decides whether anyone pays for the shot answers to the most vaccine-skeptical HHS in modern history. That gap is the trade.
Late Wednesday, Moderna announced that the FDA had approved mFlusiva — the first influenza vaccine ever built on mRNA, the same technology that ended the pandemic and then nearly ended Moderna. Eleven months ago the stock traded at $26, priced as a one-product company whose one product was disappearing. It closed Thursday near $58, up about 7% on the approval.
The approval itself is worth reading closely, because the details are unusual for a flu shot.
For adults 50 to 64, mFlusiva received full approval on the back of a 40,000-person trial showing 27% fewer flu cases than a standard licensed comparator. That is not a me-too filing — it is a superiority claim, in a category where vaccines are typically approved for producing similar antibody levels, not for preventing more disease. For adults 65 and older — the segment where the money is — the FDA granted accelerated approval based on immune-response data measured against an existing high-dose senior vaccine, with a confirmatory outcomes study still running. The safety file showed no major issues, but more short-term reactogenicity — sore arms, fever, fatigue — than today's shots.
The politics are the part the market is still underpricing, in both directions.
Earlier this year, a senior FDA official blocked the mFlusiva application outright — one visible act in the broader tightening of vaccine review under Health Secretary Robert F. Kennedy Jr. Moderna did something drugmakers almost never do: it challenged the ruling publicly. Days later the agency reversed course. In June, the FDA's independent advisory committee recommended approval unanimously. And this week the license was granted.
Read that sequence again. The first new mRNA product of the Kennedy era did not slip through a friendly agency. It was blocked, contested, adjudicated in public, and approved anyway — on superiority data. For a platform that Washington spent the last year defunding and doubting, that is the strongest possible form of validation: the kind won in a hostile room.
Briefings like this land in members' inboxes before the market prices them in. Join free →
Why does a flu shot matter to a portfolio? Because influenza is the largest recurring vaccine market in the developed world — on the order of 170 million doses distributed in the US in a normal season — and it has been a technological backwater for decades. Most flu vaccines are still grown in chicken eggs on a six-month lead time, which is why the shot you get in October was designed in February, and why in mismatch years effectiveness can fall below 20%. mRNA compresses that design cycle to weeks. A platform that can chase a drifting virus into the fall is not an incremental improvement; in a bad year it is the only product that can respond at all.
And for Moderna, flu was never the endgame. It is the wedge — the product that gets the platform back inside the routine-vaccination system, ahead of the combination COVID-plus-flu shot that is the actual commercial prize.
But here is the thing the approval headline obscures, and the reason the stock is at $58 and not $80: in American vaccines, the FDA decides what may be sold. A different body decides what gets paid for. And that body was rebuilt, member by member, by the same administration that tried to block this approval.
The rest of this briefing is for paid members: the committee mechanics that decide whether mFlusiva is covered or cash-pay, the year-one revenue math against Sanofi's senior franchise, the three scenario zones with levels from the June high to the spring floor, and the catalyst calendar through flu season.
AlphaBriefing Paid gets you every investment thesis, scenario framework, and catalyst brief we publish — the analysis private intel clients pay four figures for, at a fraction of that.